Key result
Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84) in patients with LVEF 40% or greater.
Why the study?
The efficacy and safety of finerenone in patients with heart failure and left ventricular ejection fraction 40% or greater were evaluated to improve outcomes.
Does finerenone reduce the composite risk of hospitalization for heart failure or cardiovascular death in patients with heart failure and left ventricular ejection fraction 40% or greater?
RCT
Does finerenone reduce the composite risk of hospitalization for heart failure or cardiovascular death in patients with heart failure and left ventricular ejection fraction 40% or greater?
Finerenone reduces the composite risk of heart failure hospitalization or cardiovascular death in patients with heart failure and mildly reduced or preserved ejection fraction.
Warrants consideration for HF with preserved or mildly reduced EF; extends MRA benefit to this population for the first time.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Salman Salahuddin (2026) conducted an RCT in Heart failure with preserved or mildly reduced ejection fraction. Finerenone vs. Placebo was evaluated on Composite risk of hospitalization for heart failure or cardiovascular death (rate ratio 0.84). Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84) in patients with LVEF 40% or greater.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: